BARD Score for NAFLD Fibrosis

The BARD score uses BMI, AST/ALT ratio, and diabetes to screen for advanced fibrosis in NAFLD.

BMI ≥ 28
No0Yes+1
AST/ALT ratio ≥ 0.8
No0Yes+2
Diabetes
No0Yes+1

Indicazioni d'uso

Used in adults with suspected NAFLD/MASLD to screen for advanced fibrosis (F3–F4) using routine clinical variables (BMI≥28, AAR≥0.8, diabetes). Best applied in primary care or metabolic clinics to exclude advanced fibrosis due to high NPV (≈96%) 1 [Level II evidence]. Limited for rule‑in because diagnostic accuracy is inferior to FIB‑4/NFS 2 [Level II evidence]. Used as a first‑line, low‑cost triage tool before elastography.

Approfondimenti e precauzioni

Provides rapid bedside stratification but has modest accuracy for advanced fibrosis: meta‑analysis shows AUROC ~0.76 with high NPV but poor PPV, missing many F3–F4 cases 1 [Level II evidence]. Strongly influenced by BMI and diabetes prevalence, causing frequent false positives. Should never be used alone—FIB‑4 or elastography outperform it and are recommended as primary tests 2 [Level III evidence].